CONMED Corporation (NYSE:CNMD) Receives $38.80 Average Target Price from Analysts

Shares of CONMED Corporation (NYSE:CNMD) have been given an average rating of “Reduce” by the eight brokerages that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $41.40.

A number of analysts recently weighed in on CNMD shares. BMO Capital Markets initiated coverage on CONMED in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $36.00 price target on the stock. Piper Sandler reiterated a “neutral” rating and issued a $45.00 price objective (up from $39.00) on shares of CONMED in a research report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of CONMED in a report on Monday, July 13th. Bank of America restated an “underperform” rating and set a $40.00 target price on shares of CONMED in a research report on Monday, June 29th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of CONMED in a research note on Thursday, June 4th.

CONMED Price Performance

Shares of CNMD opened at $46.38 on Friday. CONMED has a twelve month low of $31.44 and a twelve month high of $56.63. The stock’s 50 day moving average is $37.27 and its two-hundred day moving average is $38.48. The firm has a market capitalization of $1.39 billion, a PE ratio of 25.07, a P/E/G ratio of 3.30 and a beta of 0.93. The company has a current ratio of 1.48, a quick ratio of 1.04 and a debt-to-equity ratio of 0.63.

CONMED (NYSE:CNMD) last released its earnings results on Wednesday, July 29th. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.27. The company had revenue of $343.49 million for the quarter, compared to analysts’ expectations of $337.60 million. CONMED had a return on equity of 14.31% and a net margin of 4.12%.The firm’s quarterly revenue was up .3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.15 EPS. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. Research analysts anticipate that CONMED will post 4.54 earnings per share for the current year.

Institutional Trading of CONMED

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in CONMED by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 3,684,439 shares of the company’s stock valued at $149,588,000 after buying an additional 73,533 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of CONMED by 6.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,392,920 shares of the company’s stock worth $49,250,000 after acquiring an additional 80,116 shares in the last quarter. Wasatch Advisors LP purchased a new stake in shares of CONMED during the 3rd quarter worth approximately $47,026,000. Cooke & Bieler LP grew its holdings in shares of CONMED by 23.2% in the 4th quarter. Cooke & Bieler LP now owns 867,817 shares of the company’s stock worth $35,233,000 after acquiring an additional 163,494 shares during the period. Finally, Deerfield Management Company L.P. grew its holdings in shares of CONMED by 8.6% in the 3rd quarter. Deerfield Management Company L.P. now owns 760,196 shares of the company’s stock worth $35,752,000 after acquiring an additional 59,925 shares during the period.

More CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q2 results exceeded expectations. CONMED reported adjusted EPS of $1.38, above the $1.10 consensus estimate and up from $1.15 a year earlier. Revenue reached $343.5 million, surpassing the $337.6 million forecast. CONMED Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised and reaffirmed an above-consensus outlook. CONMED forecast 2026 adjusted EPS of $4.48 to $4.60, compared with analyst expectations near $4.37, while targeting 5% to 6% organic growth. Gross-margin expansion and solid international sales also supported the improved outlook. CONMED 2026 Guidance
• Positive Sentiment: Analysts increased price targets. Wells Fargo raised its target to $46 from $39, and Piper Sandler lifted its target to $45 from $39, reflecting greater confidence following the quarterly performance. Analyst Price Target Changes
• Neutral Sentiment: Management’s earnings presentation and call highlighted the quarter’s operating performance and 2026 growth priorities. The materials provide additional detail on the earnings beat, margins and guidance but do not indicate a major change to the company’s longer-term strategy. CONMED 2026 Q2 Earnings Presentation
• Negative Sentiment: Valuation and limited analyst upside may be weighing on the stock. Piper Sandler maintained a Neutral rating with a $45 target, while Wells Fargo kept an Equal Weight rating at $46—both below or near the recent trading level. Revenue growth was also modest at approximately 0.3% year over year, despite the earnings beat.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.